Finnish newco Kasvu Therapeutics has raised €30 million (US$34.4 million) in a series A financing to take forward novel small ...

Despite considerable advances in diagnosis, new gene-modifying modalities and significant regulatory inducements, there remains a long tail of rare diseases that are below the threshold required for ...

Eli Lilly and Co. has struck another major China partnership, signing a discovery-stage collaboration with Beijing-based Innocare Pharma Ltd. worth up to $3.35 billion and reinforcing the U.S.

And the hits just keep on coming for the IgA nephropathy (IgAN) space, which until 2021, had no approved therapies for treating the progressive kidney disease. Five years later, there are six ...

Med-tech financings totaled $14.58 billion through August 2026, down 23% from $19.01 billion in 2025 and the lowest eight-month total after 2023’s $11.73 billion. Volume dropped to 262 deals through ...

Palisade Bio Inc.’s clearance from the U.S. FDA this summer to start a global phase II trial with PALI-2108 in ulcerative colitis (UC) called Ascentra UC – followed Sept. 23 by word from regulators ...

Crispr genome editing could in theory be programmed to address any gene mutation, providing cures on demand for life-threatening inherited rare diseases in newborns. The challenge is to develop a ...

Pending court approval, Steri-Tech Inc., a Puerto Rico-based contract medical device sterilizer, has agreed to pay $700,000 in civil penalties as part of a settlement resolving Clean Air Act ...

Should unmodified islet cells from deceased donors be regulated as organs for transplant or as biological products? The U.S. Department of Health and Human Services (HHS) wants to know.

Anaconda Biomed SL raised $56 million in a financing round for product development and clinical work, including completion of the ongoing Athena pivotal investigational device exemption study ...

Novartis Pharma AG inked a potential $900 million deal to gain exclusive global rights to a preclinical radioligand therapy ...

A company that emerged with a new AI-powered platform nine years ago, and is focused on discovering drugs through alternative ...